Fifth Third Bancorp
ALNY icon

Fifth Third Bancorp’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fifth Third Bancorp’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.86M Sell
9,501
-67
-0.7% -$20.2K ﹤0.01% 1090
2026
Q1 		$3.17M Buy
9,568
+9,441
+7,434% +$3.21M 0.01% 975
2025
Q4 		$50.5K Buy
127
+70
+123% +$31K ﹤0.01% 1463
2025
Q3 		$26K Sell
57
-19
-25% -$7.74K ﹤0.01% 1780
2025
Q2 		$24.8K Buy
76
+6
+9% +$1.66K ﹤0.01% 1693
2025
Q1 		$18.9K Buy
70
+5
+8% +$1.28K ﹤0.01% 1771
2024
Q4 		$15.3K Buy
65
+43
+195% +$11.3K ﹤0.01% 1854
2024
Q3 		$6.05K Buy
22
+17
+340% +$4.43K ﹤0.01% 2138
2024
Q2 		$1.22K Sell
5
-3
-38% -$474 ﹤0.01% 2316
2024
Q1 		$1.2K Buy
8
+4
+100% +$667 ﹤0.01% 2256
2023
Q4 		$766 Hold
4
– – ﹤0.01% 2424
2023
Q3 		$708 Hold
4
– – ﹤0.01% 2485
2023
Q2 		$760 Hold
4
– – ﹤0.01% 2532
2023
Q1 		$801 Sell
4
-17
-81% -$3.57K ﹤0.01% 2663
2022
Q4 		$4.99K Buy
21
+3
+17% +$640 ﹤0.01% 2207
2022
Q3 		$4K Buy
18
+4
+29% +$763 ﹤0.01% 2215
2022
Q2 		$2K Buy
14
+4
+40% +$567 ﹤0.01% 2408
2022
Q1 		$2K Buy
+10
New +$1.52K ﹤0.01% 2498
2021
Q3 		– Sell
-2,341
Closed -$397K – 2635
2021
Q2 		$397K Hold
2,341
– – ﹤0.01% 769
2021
Q1 		$331K Buy
+2,341
New +$352K ﹤0.01% 792
2015
Q4 		– Sell
-14
Closed -$1K – 2727
2015
Q3 		$1K Buy
+14
New +$1.55K ﹤0.01% 2713
2014
Q4 		– Sell
-2,380
Closed -$186K – 2359
2014
Q3 		$186K Buy
2,380
+299
+14% +$19.3K ﹤0.01% 977
2014
Q2 		$131K Buy
2,081
+330
+19% +$19.6K ﹤0.01% 1089
2014
Q1 		$118K Buy
1,751
+1,257
+254% +$97.3K ﹤0.01% 1123
2013
Q4 		$32K Buy
+494
New +$29.5K ﹤0.01% 1504

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fifth Third Bancorp's ALNY Position: Q2 2026 in Review

Fifth Third Bancorp reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.7% in Q2 2026, selling an estimated $20.2K and leaving 9,501 shares worth $2.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1090.

Fifth Third Bancorp first reported a position in ALNY in Q4 2013 and has held it in 25 quarters since. The position peaked at $3.17M in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Fifth Third Bancorp held 9,501 shares of Alnylam Pharmaceuticals worth $2.86M as of Q2 2026.
  • Fifth Third Bancorp sold 67 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $20.2K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #1090 holding.
  • Fifth Third Bancorp first reported a position in Alnylam Pharmaceuticals in Q4 2013 and has held it in 25 quarters since.
  • Fifth Third Bancorp's Alnylam Pharmaceuticals position peaked at $3.17M in Q1 2026.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.